Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or dec...
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Bevacizumab, sorafenib, sunitinib and temsirolimus have been approved for use in patients with advanced solid cancers. Many other drugs with activity in preclinical models, however, have failed to show efficacy in clinical trials. The authors of this Review describe the studies that led to the approval of these antiangiogenic agents, discuss the po...
Alternative Titles
Full title
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_69255696
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_69255696
Other Identifiers
ISSN
1743-4254,1759-4774
E-ISSN
1743-4262,1759-4782
DOI
10.1038/ncponc1150
